Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 01 2021 - 7:01AM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced that it has granted a non-statutory stock option to
purchase an aggregate of 100,000 ordinary shares of Nabriva
Therapeutics as an inducement to Christine Guico-Pabia, Nabriva’s
newly appointed Chief Medical Officer. This grant was awarded
pursuant to the Nasdaq inducement grant exception as a component of
new hire employment compensation.
The stock option was granted effective October
29, 2021 with an exercise price of $1.15 per share, which is equal
to the closing price of Nabriva Therapeutics’s ordinary shares on
the date of grant. The stock option has a 10-year term and vests
over four years, with 25% of the original number of shares vesting
on the annual anniversary of the grant date until fully vested,
subject to the employee's continued service with the Company
through the applicable vesting dates. The stock option award was
approved by Nabriva Therapeutics’ Compensation Committee and was
granted as an inducement material to the new employee’s acceptance
of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option is subject to the terms and conditions of a stock
option agreement covering the grant and Nabriva Therapeutics’ 2021
Inducement Share Incentive Plan.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in
the commercialization and development of innovative anti-infective
agents to treat serious infections. Nabriva
Therapeutics received U.S. Food and Drug
Administration approval for XENLETA® (lefamulin injection,
lefamulin tablets), the first systemic pleuromutilin antibiotic for
community-acquired bacterial pneumonia (CABP). Nabriva
Therapeutics is also developing CONTEPO™ (fosfomycin) for
injection, a potential first-in-class epoxide antibiotic for
complicated urinary tract infections (cUTI), including acute
pyelonephritis. Nabriva entered into an exclusive agreement with
subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to
market, sell and distribute SIVEXTRO® (tedizolid phosphate)
in the United States and certain of its territories.
CONTACTS:
For InvestorsKim AndersonNabriva Therapeutics
plcir@nabriva.com
For MediaAndrea
GreifOgilvyandrea.greif@ogilvy.com914-772-3027
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2024 to May 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From May 2023 to May 2024